Research Keyword: vulvovaginal candidiasis

Synergistic potential and apoptosis induction of Bunium persicum essential oil and its pure components, cuminaldehyde and γ-terpinene, in combination with fluconazole on Candida albicans isolates: in vitro and in silico evaluation

mycolabadmin

Researchers tested a spice-derived essential oil called Bunium persicum and two of its active compounds to see if they could work better with the antifungal drug fluconazole against drug-resistant yeast infections. They found that one component called cuminaldehyde was particularly effective and worked synergistically with fluconazole, meaning the combination was more powerful than either treatment alone. These natural compounds could potentially help treat fungal infections that no longer respond to standard medications, offering a promising approach using plant-based remedies alongside conventional drugs.

Read More »

Impact of Clove Oil on Biofilm Formation in Candida albicans and Its Effects on Mice with Candida Vaginitis

mycolabadmin

This research demonstrates that clove oil, a natural and FDA-approved dietary supplement, can effectively combat Candida albicans infections that cause vaginal yeast infections. The study found that clove oil works by preventing the fungus from forming protective biofilms and by reducing inflammation. In mice with vaginal yeast infections, clove oil treatment significantly improved symptoms and reduced fungal levels, suggesting it could serve as a safer alternative to conventional antifungal medications.

Read More »

Synergistic potential and apoptosis induction of Bunium persicum essential oil and its pure components, cuminaldehyde and γ-terpinene, in combination with fluconazole on Candida albicans isolates: in vitro and in silico evaluation

mycolabadmin

Researchers studied how Bunium persicum essential oil and two of its active components work together with the antifungal drug fluconazole to fight resistant Candida yeast infections. They found that cuminaldehyde, one of the oil’s main components, was particularly effective when combined with fluconazole and could trigger yeast cell death. These natural compounds could offer a promising new approach to treating fungal infections that have become resistant to standard medications.

Read More »

New insights toward personalized therapies for vulvovaginal candidiasis and vaginal co-infections

mycolabadmin

Vaginal yeast infections (vulvovaginal candidiasis) and bacterial vaginosis are very common conditions affecting millions of women worldwide. Current treatments often fail or lead to antibiotic resistance. This review explores new personalized approaches including zinc supplementation, specific probiotics, and immune-boosting therapies that are tailored to each woman’s unique vaginal environment to prevent recurring infections.

Read More »

Renaming Candida glabrata—A case of taxonomic purity over clinical and public health pragmatism

mycolabadmin

Candida glabrata is a common yeast infection that causes serious illnesses in humans, affecting millions of people worldwide. Scientists have recently proposed renaming it to Nakaseomyces glabrata for technical taxonomic reasons. However, this article argues against the change because it would create confusion for doctors, complicate treatment instructions on medications, disrupt disease tracking systems, and make it harder for patients to understand their conditions. Keeping the familiar name Candida glabrata is more practical and helpful for patient care and public health than strict adherence to taxonomic classification rules.

Read More »
Scroll to Top